Johnson Investment Counsel Inc. increased its holdings in shares of Repligen Corporation (NASDAQ:RGEN – Free Report) by 8.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,308 shares of the biotechnology company’s stock after purchasing an additional 1,210 shares during the period. Johnson Investment Counsel Inc.’s holdings in Repligen were worth $1,904,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. Alliance Wealth Advisors LLC UT raised its position in Repligen by 2.5% in the 1st quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 89 shares during the last quarter. State of Michigan Retirement System raised its position in Repligen by 0.8% in the 1st quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock valued at $1,585,000 after buying an additional 100 shares during the last quarter. Louisiana State Employees Retirement System raised its position in Repligen by 0.7% in the 1st quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company’s stock valued at $1,858,000 after buying an additional 100 shares during the last quarter. State of Wyoming raised its position in Repligen by 5.2% in the 1st quarter. State of Wyoming now owns 2,338 shares of the biotechnology company’s stock valued at $297,000 after buying an additional 115 shares during the last quarter. Finally, Signaturefd LLC raised its position in Repligen by 65.3% in the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 128 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.
Repligen Stock Up 2.4%
NASDAQ:RGEN opened at $148.67 on Tuesday. The firm has a market capitalization of $8.36 billion, a price-to-earnings ratio of -594.66, a price-to-earnings-growth ratio of 2.68 and a beta of 1.08. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $182.52. The stock’s 50 day moving average price is $125.77 and its two-hundred day moving average price is $125.65. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26.
Analysts Set New Price Targets
A number of brokerages recently issued reports on RGEN. Stephens raised Repligen to an “overweight” rating and set a $160.00 target price on the stock in a research report on Tuesday, July 22nd. Hsbc Global Res raised Repligen to a “strong-buy” rating in a research report on Wednesday, October 1st. Wells Fargo & Company dropped their target price on Repligen from $180.00 to $175.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 30th. Barclays lifted their target price on Repligen from $150.00 to $160.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $180.00 target price on shares of Repligen in a research report on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Repligen has an average rating of “Moderate Buy” and a consensus target price of $169.62.
Get Our Latest Stock Report on RGEN
Insider Buying and Selling at Repligen
In other Repligen news, Director Martin D. Madaus bought 1,800 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average cost of $112.13 per share, with a total value of $201,834.00. Following the acquisition, the director owned 1,800 shares of the company’s stock, valued at $201,834. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.20% of the company’s stock.
Repligen Profile
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
See Also
- Five stocks we like better than Repligen
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- FICO’s Big Dip Could Be the Best Buying Chance of the Year
- What is Insider Trading? What You Can Learn from Insider Trading
- D-Wave: Reevaluating the Short Seller’s Case After the Downgrade
- 3 Monster Growth Stocks to Buy Now
- Datavault: A Speculative AI Play, But Beware of Volatility
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.